Fujairah Mountain Shooting Championship Returns for a New Edition in February 2025
9.9.2024 17:44:00 CEST | Business Wire | Press release
The Fujairah Shooting Club announces the important dates, side events, ambassadors and launch of the website of the second edition of Fujairah Mountain Shooting Championship
Following the resounding success of its inaugural edition in 2023, Fujairah Shooting Club has announced the return of the Fujairah Mountain Shooting Championship (FMSC) and the launch of the championship's official website for its second edition. The unparalleled and challenging sporting event will return in February 2025 and will be held under the patronage of His Highness Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah.
The championship, which will run from February 1 to 8, 2025, in Dibba, Fujairah, UAE, will feature challenging layouts, exhilarating side events, and the chance to experience the natural beauty of the Emirate. The main championship, which will be held from February 5 to 8, will feature Super Sporting with 240 clays, a total prize of USD 300,000, and USD 50,000 for 100 flash clays.
The preliminary competitions of FMSC 2025 will be held from February 1 to 4 and will feature 50 clays of English Sporting with a total prize pool of USD 40,000 across four categories. The opening ceremony will be held on February 4, and the awards ceremony is scheduled for February 8, 2025.
The main championship will feature 24 stands, each equipped with six machines and presenting ten targets, including singles and doubles. Over the course of four days, 240 targets will be set, with 60 targets to be covered each day, and participants will be organised into six-man squads to compete throughout the event.
Saif Al Zahmi, Director, FMSC, said: “Held under the patronage of H.H. Sheikh Mohammed bin Hamad Al Sharqi, Crown Prince of Fujairah, FMSC draws inspiration from the rich hunting tradition of the region and celebrate its enduring heritage. We are delighted to announce the launch of the website, kicking off the most anticipated return of the event with many new additions in February 2025. Moreover, it is a unique sporting event with over AED 1,000,000 in prizes and a chance to experience the region's vibrant culture. The competition, along with exciting side events, promises an exhilarating experience while respecting the environment through the use of ammunition with 100% natural biodegradable wads and eco-friendly clay targets suitable for all ages.”
One of the highlights of the 2025 edition is side events such as Pool Shoots and English Sporting, which will be held from February 1 to 7. Additionally, the latest edition of the championship is organised with the support of the National Sporting Clays Association and the Clay Pigeon Shooting Association, features George Digweed MBE, a renowned English sport shooter and multiple world and European clay-shooting champion; Phil Gray and Saif Bin Futtais, an Emirati sport shooter and five-time Olympian, as ambassadors.
For more information, visit fmsc.ae.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909161040/en/
Contacts
Tarek Kamal El Dine, +971 50 8829649
Tarek Kamal El Dine, +971 50 8829649
tarek@cpo.fujairah.ae
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom